NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Anbio Biotechnology

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026

$3.27+0.14 (+4.47%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 22.2
Dividend yield: –

Anbio Biotechnology income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	8.65	8.19	6.71	24
Cost of Revenue	1.10	2.30	3.35	11
Gross Profit	7.54	5.89	3.36	13
Research & Development	0.20	0.45	0.13	0.20
Selling, General & Admin	1.57	3.44	1.27	2.17
Operating Expenses	1.78	3.89	1.40	2.37
Operating Income	5.77	2.00	1.96	10
Interest Expense	–	–	–	0.01
Interest & Investment Income	0.14	0.34	0.17	0.04
Other Non-Operating Income	0.64	0.38	0.29	-0.18
Pretax Income	6.40	2.37	2.25	10
Income Tax Expense	0	0	0	–
Net Income	6.40	2.37	2.25	10
EPS (Basic)(per share)	0.15	0.06	0.11	100,112.00
EPS (Diluted)(per share)	0.15	0.06	0.11	100,112.00
Shares Outstanding (Basic, Weighted)(shares)	44	42	21	0.00
Shares Outstanding (Diluted, Weighted)(shares)	44	42	21	0.00

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 87.2%
Operating margin: 66.7%
Net margin: 74.1%
Return on equity, FY2025: 27.0%

Financial strength

Current ratio: 344.31
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 8842.3%

Valuation

P/E ratio: 22.2
Price to sales: –
Price to book: –
Dividend yield: –